Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
CGTX - Cognition Therapeutics, Inc.
Market Cap 50.65M P/E - EPS this Y -2.30% Ern Qtrly Grth -
Income -31.08M Forward P/E -1.54 EPS next Y 8.00% 50D Avg Chg -22.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -13.00%
Dividend N/A Price/Book 1.42 EPS next 5Y - 52W High Chg -72.00%
Recommedations 2.00 Quick Ratio 2.90 Shares Outstanding 40.13M 52W Low Chg 62.00%
Insider Own 0.56% ROA -93.70% Shares Float 33.94M Beta 1.40
Inst Own 28.20% ROE -108.31% Shares Shorted/Prior 709.88K/647.49K Price 1.73
Gross Margin - Profit Margin - Avg. Volume 167,724 Target Price 6.20
Oper. Margin - Earnings Date Aug 8 Volume 29,537 Change 2.98%
Healthcare | Biotechnology | United States
About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Cognition Therapeutics, Inc. News
12/20/24 B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data
12/19/24 Cognition Therapeutics announces results in Phase 2 study of CT1812
12/18/24 Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
12/13/24 We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
11/28/24 Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
07:40 AM Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis
07:30 AM Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies
11/25/24 Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population
11/15/24 Life Sciences Investor Forum: Presentations Now Available for Online Viewing
11/13/24 Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
11/12/24 Life Sciences Investor Forum Agenda Announced for November 14th
11/12/24 Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
10/31/24 Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
10/29/24 Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
10/23/24 Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
10/22/24 Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
10/09/24 Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ...
10/02/24 Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
10/01/24 Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
09/03/24 Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fletcher Aaron G.L. Director Director Nov 28 Buy 2.65 16,064 42,570 309,748 11/29/22
Kreis Leslie W. Director Director Nov 28 Buy 2.65 16,064 42,570 309,748 11/29/22
Fletcher Aaron G.L. Director Director Nov 16 Buy 1.4 71,000 99,400 307,877 11/17/22
Kreis Leslie W. Director Director Nov 16 Buy 1.4 71,000 99,400 307,877 11/17/22
Fletcher Aaron G.L. Director Director Nov 15 Buy 1.2 1,500,000 1,800,000 299,608 11/16/22
Kreis Leslie W. Director Director Nov 15 Buy 1.2 1,500,000 1,800,000 299,608 11/16/22
BIOS Memory SPV I, LP 10% Owner 10% Owner Oct 13 Buy 12 190,000 2,280,000 899,905 10/15/21
BIOS Memory SPV I, LP 10% Owner 10% Owner Oct 13 Sell 12 90 1,083 385,248 10/15/21
Fletcher Aaron G.L. Director Director Oct 13 Buy 12 190,000 2,280,000 899,905 10/15/21
Fletcher Aaron G.L. Director Director Oct 13 Sell 12 90 1,083 385,248 10/15/21
Golden Seeds Cognition Therape... 10% Owner 10% Owner Oct 13 Sell 12 33 397 2,177,985 10/15/21
Ogden CAP Associates, LLC 10% Owner 10% Owner Oct 13 Sell 12 74 889 2,210,377 10/15/21
Breedlove Mark H. Director Director Oct 13 Sell 12 12 141 404,439 10/15/21